Work

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

Year: 2019

Type: article

Abstract: , we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models. MEK inhibition increased viral replication independent of mutation status. Combination therapy increased PD-1/PD-L1 expression and PD-1 blockade further enhanced tumor regression. Further clinical development of this strategy for treating melanomas warranted.

Source: OncoImmunology

DOI: 10.1080/2162402x.2019.1571390

Authors: Praveen K. Bommareddy, Samuel D. Rabkin, Howard L. Kaufman

Institutions: Rutgers, The State University of New Jersey, Rutgers Cancer Institute, Massachusetts General Hospital, Replimune Group, Inc. (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913